You are here
AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in established RA patients who have failed prior DMARD therapy.
Two doses of upadacitinib (15 mg and 30 mg) were studied against placebo for 12 weeks and shown to produced significantly greater ACR20, ACR50, and ACR70 scores (64%, 66%, 20%, respectively).
Clinical remission was seen in 31%, 28% and 10%, of those taking 15 mg, 30 mg and placebo (p<0.001). Low disease activity was achieved in 48% of patients on upadacitinib, compared to 17% of patients on placebo).
No new or surprising safety signals were reported.
Updacitinib is being considered for other indications, including psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis.